BeiGene, Ltd.
06160
2022 6 30
2022 6 30 2021
2022 6 30 2021 6 30
107.7 14.2% 648.2 2021
6 30 321.3 131.3% 566.1
2021 6 30 429.0 83.9%
82.1
2022 6 30 2021 6 30
370.3 31.9% 1,530.9
2022 6 30 2021 6 30
591.9 143.0% 1,005.7
2022 6 30 0.75
2021 6 30 0.35 114.3%
1
6 30
2022 2021
13 566,084 244,741
3 82,114 511,123
648,198 755,864
136,410 68,948
768,122 676,817
625,976 414,395
376 375
1,530,884 1,160,535
(882,686) (404,671)
21,502 (9,045)
(117,650) (4,990)
(978,834) (418,706)
9 26,889 (4,860)
(1,005,723) (413,846)
(0.75) (0.35)
15 1,334,252,648 1,191,521,766
(9.80) (4.52)
102,634,819 91,655,520
2
6 30
2022 2021
(1,005,723) (413,846)
(88,085) 5,864
– 361
(12,315) (1,072)
(1,106,123) (408,693)
3
2022 2021
6 30 12 31
4,531,137 4,375,678
4 333 328
4 1,172,554 2,241,962
5 172,259 483,113
6 262,210 242,626
10 207,383 270,173
6,345,876 7,613,880
4 3,939 6,881
7 633,100 587,605
117,583 117,431
8 43,325 46,679
9 103,429 110,424
10 130,955 163,049
1,032,331 1,032,069
7,378,207 8,645,949
11 234,355 262,400
10 454,183 558,055
3 163,396 187,414
9 15,564 21,395
24,788 21,925
3 125,394 120,801
12 380,729 427,565
1,398,409 1,599,555
4
2022 2021
6 30 12 31
12 185,207 202,113
3 167,570 220,289
41,921 43,041
9 14,739 14,169
3 219,385 269,561
10 48,432 54,234
677,254 803,407
2,075,663 2,402,962
20
0.0001
9,500,000,000
2022 6 30 2021 12 31
1,349,639,439
1,334,804,281 134 133
11,356,686 11,191,007
17 (82,450) 17,950
(5,971,826) (4,966,103)
5,302,544 6,242,987
7,378,207 8,645,949
5
6 30
2022 2021
(1,005,723) (413,846)
32,061 21,159
16 146,860 110,624
4 23,529 6,033
– 53,500
3 (45,583) (53,902)
7,550 (12,311)
6,360 11,212
307,430 (13,338)
(31,633) (28,294)
32,315 (77,204)
(30,362) (42,558)
19,525 1,688
(76,737) 138,877
(2,114) 3,189
(616,522) (295,171)
(95,421) (80,920)
(11,504) (1,357,051)
1,051,028 1,997,515
(75,000) (8,500)
– (7,500)
869,103 543,544
6
6 30
2022 2021
12 – 10,819
12 67,586 112,589
12 (115,405) (15,959)
18,972 35,601
(28,847) 143,050
(71,212) 5,257
152,522 396,680
4,382,887 1,390,005
4,535,409 1,786,685
4,531,137 1,776,448
333 310
3,939 9,927
24,436 14,527
12,899 14,267
58,676 28,885
– 45,000
7
2021 12 31 1,334,804,281 133 11,191,007 17,950 (4,966,103) 6,242,987
– – (152) – – (152)
2,165,904 – – – – –
12,669,254 1 18,971 – – 18,972
– – 146,860 – – 146,860
– – – (100,400) – (100,400)
– – – – (1,005,723) (1,005,723)
2022 6 30 1,349,639,439 134 11,356,686 (82,450) (5,971,826) 5,302,544
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,552,749) 3,869,243
(1,722,773) – – – – –
15,467,855 2 35,599 – – 35,601
– – 110,624 – – 110,624
– – – 5,153 – 5,153
– – – – (413,846) (413,846)
2021 6 30 1,204,567,023 120 7,561,155 12,095 (3,966,595) 3,606,775
8
1.
BTK)
PD-1
PARP1 PARP2
13
2,500
40 80
30 3
16,000
CMO
2010 29
8,600
2022 6 30 45
BeiGene 101 – 100%
BeiGene AUS Pty Ltd 56,947,230 100%
BeiGene Australia
* 902,345,067 100%
* 10,450,000,000 100%
BeiGene (Canada) ULC 100 100%
9
BeiGene ESP, S.L. 3,000 100%
BeiGene France Sarl 7,500 100%
* 8,870,000,000 100%
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
BeiGene (Hong Kong) Co., Limited 1 100%
7,700,000,000
* 4,000,000 100%
BeiGene International GmbH 20,000 100%
BeiGene (Italy) S.R.L 10,000 100%
BeiGene Brazil Ltda. 2,450,190 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene Sweden AB 25,000 100%
BeiGene Turkey Medical Products 10,000 100%
Trade Limited Company
BeiGene Ireland Limited – 100%
BeiGene Ireland
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 100,000,000 100%
BeiGene Netherlands B.V – 100%
10
BeiGene NZ Unlimited 100,000 100%
BeiGene NZ, Limited
BeiGene Pharmaceuticals GmbH 20,000 100%
* 3,800,000 100%
BeiGene Pharmaceuticals Israel Limited – 100%
* 7,000,000 100%
* 1,000,000 100%
* 934,344,311 100%
* – 100%
* 270,000,000 100%
BeiGene Singapore Pte. Ltd. 1 100%
* 2,673,218,389 100%
BeiGene Switzerland GmbH 20,000 100%
BeiGene Switzerland
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 142 100%
BeiGene United Kingdom, Ltd. 110 100%
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC – 100%
11
BeiGene US Manufacturing Co., Inc. 156,000,000 100%
BeiGene Hopewell Urban Renewal, LLC 115,000,000 100%
Pi Health, Ltd. 12,000,000 100%
Pi Health USA, LLC 5,000,000 100%
B10 Health Technologies Private Limited – 100%
Newco 101 – 100%
*
2022 6 30 2022 2021 6 30
2022 2021 6 30
2022 2021 6 30
10-Q S-X 10
2021 12 31 10-K
2022 6
30
12
2021 11 2021-10 832
2021 12 15
2021 12 31
2022 6 30
2.
1
13
2 1
3
2022 6 30 2021 12 31
2022 6 30 1 2 3
384,121 – –
257,614 – –
4
1,172,554 – –
4 :
8,451 3,003 –
– – 5,000
1,822,740 3,003 5,000
2021 12 31 1 2 3
107,855 – –
315,564 – –
4
2,241,962 – –
4 :
23,809 10,306 –
2,689,190 10,306 –
14
3
Leap Therapeutics, Inc. Leap
2020 1
2021 9 Leap Leap
1 Leap 2
4
3
2022 6 30 2021 12 31
3.
2022 2021 6 30
2022 2021 6 30
6 30
2022 2021
– 484,646
24,240 26,477
52,497 –
5,377 –
82,114 511,123
15
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2) (3)
606
650,000,000
1,231,000,000
420,000,000
484,646,000
165,354,000
16
2021 6 30
2021 6 30
2022 6 30 20,656,000 2021
6 30 26,477,000 2022 6
30 5,377,000
2021 12
TIGIT
5
2022
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000
1,150,000,000
50%
25%
606
(1)
(2)
(3) (4)
17
300,000,000
71,980,000 213,450,000
14,570,000
2022 6 30
52,497,000 2022 6 30
3,584,000
2019 10
2020 1 2
XGEVA 2019 2020 11
2020 7
2020 12
B
2021 7
2022 4
CD19 B
18
1,250,000,000
K R A S G12C
LUMAKRAS(sotorasib)
LUMAKRAS
808
100%
2022 4 20
2019 10
2020 1 2 174.85
15,895,001 20.5%
Anthony Hooper
2020 1
132.74 2,109,902,000
601,857,000
2,779,241,000 2,162,407,000
616,834,000
19
2022 2021 6 30
6 30
2022 2021
46,789 55,330
45,583 53,903
92,372 109,233
2022
6 30
698,687
2022 6 30 2021 12 31
2022 2021
6 30 12 31
125,394 120,801
219,385 269,561
344,779 390,362
2022 2021 6 30
6 30
2022 2021
3,478 678
898 63
(26,642) (15,917)
(22,266) (15,176)
2022 6 30
30,061,000 2021 6 30 18,854,000
2022 6 30 2021 12 31 101,580,000
106,790,000
20
4.
2022 6 30 2021 12 31 4,272,000
7,209,000
2022 6 30
1,184,869 – 12,315 1,172,554
1,184,869 – 12,315 1,172,554
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
2022 6 30
2022 6 30
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap
Leap 2021 9 Leap
7,250,000 Leap 2022 6 30
Leap 8.3%
Leap 13.1%
2022 6 30 22,661,000 2021 6 30
5,376,000 2022 6 30 2021 12 31
21
2022 2021
6 30 12 31
Leap 8,451 23,809
Leap 3,003 10,306
2022 6 30 2021 12 31
44,033,000 43,722,000
2022 6 30
366,000
2022 6 30 2021 12 31
27,100,000 22,955,000
2022 6 30
1,234,000 2021 6 30 657,000
5.
2022 2021
6 30 12 31
172,467 483,528
(208) (415)
172,259 483,113
45 90
2022 2021
6 30 12 31
3 171,294 483,058
3 6 965 55
172,259 483,113
22
2022 2021 6 30
6 30
2022 2021
415 112
(210) (46)
– –
3 1
208 67
6.
2022 2021
6 30 12 31
82,848 78,140
37,992 9,397
141,370 155,089
262,210 242,626
7.
2022 2021
6 30 12 31
65,485 65,485
131,885 118,203
50,878 50,288
179,495 144,083
138,478 119,585
36,473 27,404
602,694 525,048
(142,561) (124,286)
172,967 186,843
633,100 587,605
23
2021 11 75,197,000 42
2022 6 30 30,041,000 2021 6 30
20,667,000
8.
2022 6 30 2021 12 31
2022 6 30 2021 12 31
7,500 (3,625) 3,875 7,500 (3,250) 4,250
42,016 (2,566) 39,450 43,394 (965) 42,429
816 (816) – 816 (816) –
50,332 (7,007) 43,325 51,710 (5,031) 46,679
BMS
10
2018 9
2020 2
2024 2
12
6 30
2022 2021
1,644 117
376 375
2,020 492
24
2022 6 30
12 31
2022 1,614 375 1,989
2023 3,222 750 3,972
2024 3,222 750 3,972
2025 3,222 750 3,972
2026 3,222 750 3,972
2027 24,948 500 25,448
39,450 3,875 43,325
9.
2022 6 30 26,889,000 2021 6 30
4,860,000 2022 6 30
2021
6 30
2022 6 30
2022 6 30 11,765,000 12
2022 6 30
1,840,000
2022 6 30
2021 12 31
2022 6 30 2013 2022
2012 2022 2018 2022
2015 2022
2011 2022
25
10.
2022 2021
6 30 12 31
72,474 87,239
59,291 78,538
18,627 58,579
17,409 12,010
2,611 5,052
8,462 1,695
28,509 27,060
207,383 270,173
2022 2021
6 30 12 31
109 109
14,412 14,140
(1) 21,473 24,237
29 17,162
7,345 6,609
4 87,587 100,792
130,955 163,049
(1)
26
2022 2021
6 30 12 31
124,565 139,966
151,321 213,922
55,366 71,560
23,525 45,661
71,512 59,639
27,894 27,307
454,183 558,055
2022 2021
6 30 12 31
40,835 46,352
7,484 7,814
113 68
48,432 54,234
11.
2022 2021
6 30 12 31
3 229,217 257,977
3 6 1,725 3,210
6 1 3,137 1,110
1 276 103
234,355 262,400
27
12.
2022 6 30 2021 12 31
2022 6 30 2021 12 31
2018 4 4 580,000 9 2027 4 4 (1) 4,330 29,000 1,255 8,000
2020 1 22 (2) 9 2029 1 20 (2) 1,493 10,000 1,569 10,000
2020 11 9 378,000 9 2029 11 8 (3) 2,613 17,500 – –
2020 9 24 200,000 (4) 4.5% 200,000 1,339,585 200,000 1,274,535
2020 9 24 500,000 (5) 4.5% 14,930 100,000 15,693 100,000
2022 2 25 50,000 1 2023 2 25 2.2% 50,000 334,896 – –
(6) 107,363 719,115 209,048 1,332,197
380,729 2,550,096 427,565 2,724,732
2018 4 4 580,000 9 2027 4 4 (1) 81,368 545,000 89,444 570,000
2020 1 22 (2) 9 2029 1 20 (2) 50,016 335,000 53,353 340,000
2020 11 9 378,000 9 2029 11 8 (3) 53,823 360,500 59,316 378,000
185,207 1,240,500 202,113 1,288,000
1. 2022 6 30
4.9%
2022 6 30 598,000
4,000,000
2. 2020 1 22
1,100,000,000
2020 12 31
1,100,000,000 350,000,000 2022 6 30 4.4%
2022 6 30 771,000 5,000,000
2017 3 3
3. 2022 6 30
4.3%
28
4. 2020 9 200,000,000
120,000,000
80,000,000 2021 10 8
2021 10 8 2022 10 8
2017 1
25
5. 2020 9
73,640,000 500,000,000
14,728,000 100,000,000 58,912,000
400,000,000
(i)2021 11 9
(ii) 2021 10 8
(i)2022 11 9
(ii) Hillhouse Capital
Hillhouse Capital Hillhouse
Capital
6. 2021 12 31 2020 12 31
1,760,000,000
2021 4 19 2023 5 24 2022 6 30
17,586,000 117,000,000 114,036,000
730,082,000 2022 6 30
4.1%
2022 6 30 10,984,000 1,935,000
2021 6 30 14,577,000 251,000
29
13.
2022 2021 6 30
6 30
2022 2021
638,273 291,794
(72,189) (47,053)
566,084 244,741
2022 2021 6 30
6 30
2022 2021
233,072 64,513
192,522 123,758
41,576 26,775
29,008 17,792
19,798 –
21,396 –
8,405 –
8,946 6,961
4,577 2,221
6,784 2,721
566,084 244,741
2022 2021 6 30
6 30
2022 2021
59,639 11,874
72,189 47,053
(60,316) (33,355)
71,512 25,572
30
14.
6 30
2022 2021
136,410 68,948
30,041 20,784
768,122 676,817
13,366 10,141
2,020 375
489,416 316,935
146,860 110,632
25,966 17,523
662,242 445,090
118,355 2,460
(32,520) (5,534)
73 –
2022 2021 6 30 293,291,000 220,110,000
15.
6 30
2022 2021
(1,005,723) (413,846)
1,334,252,648 1,191,521,766
2022 2021 6 30
31
16.
2016
2016 1 NASDAQ (IPO)
2016 2016 2016 2
65,029,595 2016 2011
2011 2016
2011
2022 6 30 2011 2016
5,166,510 2018 12 2016 38,553,159
2020
6 2016 57,200,000
2030 4 13 2016
2022 6 30 2016 12,159,745
33,193,771 2022 6 30 2016
63,489,649 57,144,906 2022 6 30
2016 74,479,333
2016 2016
2016 66,300,000
2022 3 31 5% 2022 6 22
2018
2018 6 2018 2018
12,000,000
5635(c)(4)
5635(c)(4) 2018
2018
2016 2018 8
2018
2022 6 30 2018
2022 6 30 2018
30,901 408,408
2016 2018 2022 6 22
32
2018
2018 6 2018
3,500,000 2018 12
3,855,315 7,355,315
2019 6 2021 6
2021 9 1
6
15%
10%
2022 6 30 4,527,386
1 2
2022 2 28 667,160 210.52 16.19 178.94 13.76 9,183
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
1
2
2022 2021 6 30
6 30
2022 2021
67,965 52,082
78,895 58,542
146,860 110,624
33
17.
2021 12 31 27,898 (3,700) (6,248) 17,950
(88,085) (12,315) – (100,400)
– – – –
(88,085) (12,315) – (100,400)
2022 6 30 (60,187) (16,015) (6,248) (82,450)
18.
2019 10 31 2019 12 6 2020 9 24
2021 9
165,529 2,151,877 50,000,000
2021 12
192.60 391.68
115,055,260
3,392,616,000
19.
10%
50%
34
10%
2022 6 30 2021 12 31
2,448,530,000 799,574,000
20.
2022 6 30 109,700,000 65,020,000
44,680,000
2022 6 30 308,141,000
1,250,000,000 2022
6 30 698,687,000
2021 6
2022 6 30 25,173,000
15,000,000 2022 6 30
12,750,000
2022 6 30
1,536,000
35
CRO
21.
(a) 2022 2021 6 30
2022
2021 6 30 (i)
50,000 2021 50,000 (ii) 75,000 2021
75,000 (iii) 2,141,000 2021
2,271,000
(b)
6 30
2022 2021
3,423 2,945
37 65
19,626 17,635
23,086 20,645
22.
6 30
2022 2021
403,164 218,617
213,749 383,809
31,285 153,438
648,198 755,864
36
2022 2021 6 30 2022
6 30 57,480,000
156,269,000 2021 6 30 357,786,000
26,023,000 2022 6 30
24,634,000
6,651,000
2021 6 30
23.
2022 6 30
(i) (iii)
(768,122) (5,520) – (773,642)
(625,976) (4,044) – (630,020)
(978,834) (9,564) – (988,398)
(26,889) 1,082 (11,385) (37,192)
(1,005,723) (8,482) (11,385) (1,025,590)
(1,005,723) (8,482) (11,385) (1,025,590)
2021 6 30
(i) (iii)
(676,817) 34,210 – (642,607)
(414,395) 18,197 – (396,198)
(418,706) 52,407 – (366,299)
4,860 (4,125) (21,801) (21,066)
(413,846) 48,282 (21,801) (387,365)
(413,846) 48,282 (21,801) (387,365)
37
2022 6 30
(i) (ii) (iii)
103,429 1,082 – (9,662) 110,169
15,320* – –
7,378,207 16,402 – (9,662) 7,384,947
11,356,686 9,564 307,894* 1,723 11,985,971
174,049* – 136,055*
(5,971,826) (9,564) (307,894)* (11,385) (6,594,371)
1,082 – –
(158,729)* – (136,055)*
5,302,544 16,402 – (9,662) 5,309,284
2021 12 31
(i) (ii) (iii)
110,424 5,253 – – 125,744
10,067* – –
8,645,949 15,320 – – 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(4,966,103) (48,730) – (56,237) (5,568,781)
5,253 – –
(115,252)* (307,894)* (79,818)*
6,242,987 15,320 – – 6,258,307
*
38
(i)
2022 6 30
9,564,000
2021 6 30 52,407,000 2022 6 30
1,082,000 2021 6 30
4,125,000
2021 12 31
174,049,000
15,320,000 158,729,000 2021 12 31
2022 1 1
(ii)
2016 2
307,894,000
307,894,000
39
(iii)
2016-09
2022 6 30
9,662,000 2021 6 30
2022 6 30 1,723,000
2021 6 30 21,801,000
2021 12 31 136,055,000
136,055,000 2022 1 1
(iv)
2019 1 1
16
2022 6 30 2022 6 30
(v)
2022 6 30 2022 6 30
24.
2022 6 30 2021 6
30
40
3
BTK)
PD-1
PARP1 PARP2
13
2,500
40 80
30
3
16,000
CMO
2010
29 8,600
41
2022 8 23 NMPA
(ESCC) (sBLA)
2022 8 9 3 RATIONALE 301
(HCC)
(OS)
600
2022 7 14 FDA
ESCC (2L) (BLA)
FDA
BLA FDA
2022 6 30 2022 (ESMO)
RATIONALE 306 RATIONALE 306 3
ESCC
2022 6 21 NMPA
PD-L1 (G/GEJ)
sBLA
2022 6 13
(MCL)
NewBridge Pharmaceuticals
(MENA)
MENA
2022 6 13
(CLL)
(SLL) (sNDA) FDA
(PDUFA) 2023 1 20 FDA
PDUFA
sNDA
3 ALPINE
(IRC) CLL SLL
42
(ORR) 2022 4 11
2022 6 10 NMPA
(NPC)
1. 800
ociperlimab
TIGIT
BGB-11417 BCL2
2022
BGB-A445 OX40 surzebiclimab TIM3
BGB-10188 PI3K BGB-15025 HPK1 BGB-16673
BTK CDAC BGB-23330 TYK2 BGB-24714 SMAC
50
2.
2,500
CRO
43
3.
3,100
4.
WM
50
5.
44
2021 1
(1)
(2)
2021 12
TIGIT
5
(1)
(2)
(3)
45
46
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
BGB-10188 PI3Kδ
BGB-23339 2(TYK2)
LBL-007 LAG-3
Sitravatinib Mirati Therapeutics, Inc Mirati
ZW25(Zanidatamab) ZW49 Zymeworks Inc Zymeworks
HER2
(BAT1706)
47
48
ADS
49
2021 12
2022 2021 6 30
6 30
2022 2021 %
566,084 244,741 321,343 131.3%
82,114 511,123 (429,009) (83.9)%
648,198 755,864 (107,666) (14.2)%
136,410 68,948 67,462 97.8%
768,122 676,817 91,305 13.5%
625,976 414,395 211,581 51.1%
376 375 1 0.3%
1,530,884 1,160,535 370,349 31.9%
(882,686) (404,671) (478,015) 118.1%
21,502 (9,045) 30,547 (337.7)%
(117,650) (4,990) (112,660) 2,257.7%
(978,834) (418,706) (560,128) 133.8%
26,889 (4,860) 31,749 (653.3)%
(1,005,723) (413,846) (591,877) 143.0%
50
2021 2022 6 30
2022 6 30 2021 6 30
7.559 6.482 14.2%
6.50
2022 2021 6 30
6 30
2022 2021 %
566,084 244,741 321,343 131.3%
– 484,646 (484,646) (100.0)%
24,240 26,477 (2,237) (8.4)%
52,497 – 52,497
5,377 – 5,377
82,114 511,123 (429,009) (83.9)%
648,198 755,864 (107,666) (14.2)%
6 30
2022 2021 %
233,072 64,513 168,559 261.3%
192,522 123,758 68,764 55.6%
41,576 26,775 14,801 55.3%
29,008 17,792 11,216 63.0%
21,396 – 21,396
19,798 – 19,798
8,946 6,961 1,985 28.5%
8,405 – 8,405
4,577 2,221 2,356 106.1%
6,784 2,721 4,063 149.3%
566,084 244,741 321,343 131.3%
51
2022 6 30 131.3% 5.661
2.447
2021 8 2022 1
2022 1
2022 2022 6 30
2022 6 30
2.331
261.3% 2022 6 30
1.563
2,600 500.5%
2022 6 30
7,020 82.7% (CLL)
(SLL)
2022 6 30
1.925
1.238 55.6% 2022 6 30
2021 3 1 2021 2,810
2021
2022 6 30 8,210
2022 6 30
2,420
5,250
540 2021 6 30 5.111
4.846
2021 6 30 2,650
3
2021 6 30 6,890 2022 6 30
1.364
2021 8
2022 1
52
2022 6 30 4.297 2021 6
30 1.758
71.8% 2022 6 30
75.9%
2022 1 2022 6 30
2021 6 30
2021 6 30 6.768 9,130
13.5% 2022 6 30 7.681 2022
2021 6 30
6 30
2022 2021 %
232,009 219,433 12,576 5.7%
– 53,500 (53,500) (100.0)%
1
46,789 55,330 (8,541) (15.4)%
278,798 328,263 (49,465) (15.1)%
489,324 348,554 140,770 40.4%
768,122 676,817 91,305 13.5%
1
2022 6 30 9,240
4,680 4,560
2022 6 30
5,350
53
1.408 40.4% 4.893
6,500
4,320
2,570
1,590
910
2021 6 30 4.144 2.116
51.1% 2022 6 30 6.260
1.174
3,710
3,670
2,030
54
2021 6 30 900
3,050 337.7% 2022 6 30 2,150
2021
2021 6 30 500
2022 6 30 1.177
Leap Therapeutics
2022 6 30 2,690 2021 6 30
490 2022 6 30
2021 6 30
2022 6 30
(1) 21.0 (2) 237.0
35.0 (3) 37.5
2021 12 31 483.1 64.3% 2022 6 30
172.3 3.0
55
2021 12 31 242.6 8.1% 2022 6 30
262.2
2022 2021
6 30 12 31
72,474 87,239
59,291 78,538
18,627 58,579
17,409 12,010
2,611 5,052
8,462 1,695
28,509 27,060
207,383 270,173
2021 12 31 587.6 7.7% 2022 6
30 633.1
2022 6 30 2021 12 31
234.4 262.4
56
2022 2021
6 30 12 31
3 229,217 257,977
3 6 1,725 3,210
6 1 3,137 1,110
1 276 103
234,355 262,400
2022 6 30 2021 12 31
2022 2021
6 30 12 31
124,565 139,966
151,321 213,922
55,366 71,560
23,525 45,661
71,512 59,639
27,894 27,307
454,183 558,055
2021 12 31 558.1 18.6%
2022 6 30 454.2 2022 6 30
57
2022 6 30 2021 12 31
2022 2021
6 30 12 31
4,535,409 4,382,887
1,172,554 2,241,962
565,936 629,678
(BMS)
2022 6 30
10 2021 6 30 4.138
2022 6 30 60
2017 9
2022 6 30
12
2021 1
6.5
2021 12
TIGIT
2022
1 3
58
2022 2021 6 30
6 30
2022 2021
4,382,887 1,390,005
(616,522) (295,171)
869,103 543,544
(28,847) 143,050
(71,212) 5,257
152,522 396,680
4,535,409 1,786,685
2022 6 30 6.165
10 2.184 1.708
Leap
2021 6 30 2.952
4.138 1,760
1.363
59
2022 6 30 8.691
11 1,150 9,540
7,500
2021 6 30 5.435
20 14 8,090
850 750
2022 6 30 2,880
1.154 6,760
1,900
2021 6 30 1.431
1.126
3,560 1,080
1,600
2022 6 30
530
7,120
60
2020 5
61
2022 6 30
71,364 14,282 57,082
109,700 51,358 58,342
565,936 380,729 185,207
40,909 13,896 27,013
698,687 254,109 444,578
12,750 4,250 8,500
25,173 5,743 19,430
7,484 1,536 5,948
308,141 308,141 –
1,840,144 1,034,044 806,100
2022 6 30 1.097
6,500 BMS
4,470 BMS
3.807 1.852
12
62
12.5
2022 6 30 6.987
1,500 2022
6 30 1,280
2021 6
2022 6 30 2,520
2022 6 30
150
2022 6 30 3.081
42 7,520
2022 4 29
63
2022 6 30 2021 12 31
45 44 430 720
12 22
2022
6 30
100 2022 6 30
660 660
2022 6 30 2021 12 31 1.723
4.831
64
2005
2022 6
30 2021 12 31 5.1%
2.3% 2022 6 30
1.177
1994
(PBOC)
65
2022 6 30
2022 6 30
2021 12 31 10.1% 10.7%
2022 6 30
2022 6 30
2022 6 30
2022 6 30
2022 6 30 8,600 2021
12 31 8,000
2022 6 30 662.2 2021 6
30 445.1
66
2022 6 30 4.3
2021 12 31 7.2 2022 6
30
132.1 2021 12 31 145.8
2022 6 30 2021 12 31
2022 6 30 2021 6
30
1
67
C.2.1
Ranjeev Krishana
3.21
D.3.3 D.3.7
Thomas Malley Corazon (Corsee)
D. Sanders Anthony C. Hooper Thomas
Malley 3.10(2) 3.21
68
3.25
E.1.2
Ranjeev Krishana
2022 6 22
B.3.1
Donald W. Glazer
Michael Goller Alessandro Riva Anthony
C. Hooper Donald W. Glazer
69
B.8
13.51(B)(1)
13.51(B)(1)
2022 1 31
Margaret Han Dugan 2022 2 1
2022 2 25
Alessandro Riva 2022 2 1
2022 6 22
70
2020 1 2
174.85 15,895,001
206,635,013
20.5% 2,779,241,000 (a) 2019 10
30 30
36% (b) 1.00 7.84 2019
10 31 26% (c)
2019 10 31 26%
2019 11 29
2022 6 30
2022
2021 2022 6 30
12 31 6 30
(%)
(a)
2,779,241 100% 1,869,643 1,984,939 794,302
(a)
12.5
2019 11 29
2025 2019 11 1
2019 12 9 2020 1 3
2020 9 24
20.6%
20.4% 75,000,000
71
90
2020 12 1
(a) 20%
(b) 60 (c)
2020 3 18 2020 9 25
2020 10 9
2021 9
165,529 2,151,877
50,000,000 2022 6 30 50,000,000
2020 7
2020 7 15 2020
202,995,338
2020 7 12 14.2308
185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2022 6 30 19.2 1.5
72
2021 12 15
2021 6 16 2021
192.60
234.89 391.68
115,055,260
3,392,616,000
(i)
(ii) (iii) (iv)
(v)
2020 11 16 2021 1 29 2021
4 20 2021 5 14 2021 6 1 2021 6 21 2021 6 28
2021 6 30 2021 7 9 2021 7 28 2021 10 15 2021
11 16 2021 11 23 2021 11 24 2021 11 29 2021
11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13
2021 12 21 2021 12 28 2022 4 29 2021
4 30
2022 6 30 47 169
2022 6 30
2021 2022 2022
12 31 6 30 6 30
13,245,940 – 3,309,549 9,936,391
467,700 – 348,120 119,580
150,000 – 91,092 58,908
136,360 – 62,207 74,153
6,000,000 – 913,798 5,086,202
1,630,155 – – 1,630,155
21,630,155 – 4,724,766 16,905,389
73
Thomas Malley
Anthony C. Hooper Corazon (Corsee) D. Sanders Thomas Malley
Corazon (Corsee) D. Sanders Anthony C. Hooper
Thomas Malley
2022 6 30
2022 6 30
(www.hkexnews.hk)
(www.beigene.com) 2022 6 30
2022 8 26
Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
74